Surgery Partners (SGRY) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- $0.10
- Estimate
- $0.06
- Surprise
- +59.6%
- Revenue (period 2026-06-30)
- $848.9M
- Score today
- 5.0/10
Revenue source: xbrl.
How the report landed
Surgery Partners (SGRY) beat the $0.06 estimate with adjusted EPS of $0.10 — a large 59.6% upside surprise.
Where TrendMatrix's rating stands now
TrendMatrix currently rates SGRY Sell at 5.0/10; no pre/post engine snapshot brackets this report.
2 of the last 4 quarters beat the estimate; this quarter's +59.6% surprise compares with a +14.7% four-quarter average. Next scheduled report: 2026-11-09.
What argues against it
- Concentration risk — Customer: private insurance payors (52.0%)
- Target reached (-18.7% upside)
- Quality below floor (3.3 < 4.0)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $23.23
- Stop
- $21.61
Risk check: RSI 94 — a level conventionally read as overbought; gains at these levels often lean on momentum.
Model outputs from TrendMatrix’s engine as of 2026-10-29 — shown for context, not personalized investment advice.
SGRY at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Medical Care Facilities
- Market cap
- $3.00B
- P/E (fwd)
- 111.7
- 52-week range
- $11.41–$23.44
- Off 52-week high
- 0.9%
- RSI (14)
- 94
- Volume vs avg
- 0.09×
- Score today
- 5.0/10